Exenatide is an injectable drug in the new class of incretin mimetics, PBS listed from 1 August 2010 for type 2 diabetes. The listing is for combination therapy as either:
- dual therapy, with metformin or a sulfonylurea, where HbA1c exceeds 7% and the patient cannot take these drugs together, or
- triple therapy, with metformin and a sulfonylurea, where HbA1c exceeds 7% despite maximally tolerated doses of both drugs.